CHICAGO – Many U.S. adults believe that only extremely effective drugs without serious adverse effects are approved, but providing explanations to patients highlighting uncertainties about drug benefits may affect their choices, according to a report in the September issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The article is part of the journal's Less Is More series.
Approval from the U.S. Food and Drug Administration (FDA) does not necessarily ensure that a drug has a large or important benefit, or that all serious adverse effects of the drug are known, according to background information in the article. "Uncertainties are greatest in the first few years after approval and for drugs approved solely on the basis of a surrogate outcome," the authors note. They point out that the cholesterol-lowering drugs Zetia and Vytorin reached $1.8 billion in sales in 2007 before a study found no clinical benefit from these drugs, and that the anti-inflammatory medication Vioxx reached $2.4 billion in sales by 2003 before being withdrawn from the market due to its association with myocardial infarctions (heart attacks) and strokes. "The FDA has never required advertisements to acknowledge uncertainties inherent in all new drugs," write the authors. "Enthusiasm for Zetia and Vioxx … might have been dampened had consumers known to look for drugs approved based on patient outcomes or drugs with a longer safety record."
Lisa Schwartz, M.D., M.S., and Steven Woloshin, M.D., M.S., from the VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt., and the Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, N.H., conducted an Internet-based, randomized, controlled trial of U.S. adults' beliefs and choices regarding prescription drug uncertainties. The 2,944 participants were randomized to three explanations about a pair of cholesterol drugs, one that was approved because of a surrogate outcome (lower cholesterol) and another that was approved because of a patient outcome (reduced myocardial infarctions). Participants in the control group received no explanation, those in the nondirective group were told that surrogate outcomes do not always translate into patient outcomes and those in the directive group received the same explanation as well as advice to "Ask for a drug shown to reduce heart attacks."
In a second randomization, participants received one of three explanations about a pair of heartburn drugs, one that was newly approved and another that was approved eight years earlier. Participants in the control group received no explanation, those in the nondirective group were told "It takes time to establish the safety of new drugs" and those in the directive group were advised to "Ask for a drug with a longer track record."
The primary outcome was choice of the drug for which there was less uncertainty. In the cholesterol drug example, the better choice would be the drug that had a beneficial effect on patient outcome (reducing myocardial infarction) instead of surrogate outcome (lowering cholesterol). In the heartburn drug example, the better choice would be the drug that was approved eight years earlier instead of the recently approved drug. Researchers also asked participants, "What would you do if your doctor recommended the drug with the surrogate outcome? Do you think new—or old—drugs are safer?" and assessed their understanding of FDA approval with four true/false questions.
One-quarter of participants mistakenly believed that the FDA approves only drugs without serious side effects, and more than one-third mistakenly believed that the FDA approves only "extremely effective" drugs. Equal percentages of participants in the directive and nondirective groups (71 percent in the cholesterol drug example and 53 percent in the heartburn drug example) chose the drug for which there was less uncertainty. In both examples, choice of the drug for which there was less uncertainty was lowest among the control group (59 percent and 34 percent, respectively). When asked what they would do if their physician recommended the drug approved for a surrogate outcome, 61 percent, 58 percent and 49 percent of participants in the directive, nondirective and control groups, respectively, said they would request the drug approved for a patient outcome. When asked which of the heartburn drugs was safer, 46 percent, 45 percent and 31 percent of the directive, nondirective and control groups, respectively, selected the older drug. The proportion of participants who chose the older heartburn drug and said it was safer was 40 percent, 41 percent and 26 percent, respectively. One limitation the authors note is "participants were making hypothetical choices between drugs."
"There are important gaps in what people know about prescription drugs—gaps that undoubtedly contribute to the rapid uptake of drugs despite uncertainty about benefit and harm," write the authors. "Our findings show that simple explanations (ones that are brief enough even for television advertisements) help consumers make better decisions." They recommend that the FDA more effectively communicate what it knows and does not know about how well drugs work.
(Arch Intern Med. 2011;171[16]:1463-1468. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This study was supported by a grant from the Attorney General Consumer and Prescriber Education grant program and Robert Wood Johnson's Pioneer Program. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Using Patients to Promote Evidence-Based Prescribing
In an accompanying commentary, Michael A. Steinman, M.D., from the San Francisco VA Medical Center, considers the implications of the study by Schwartz and Woloshin, which he calls "a patient-oriented approach to promote use of drugs with proven clinical benefit and a well-established track record of safety." Although study participants who received the explanations about the drugs were more likely to choose the drug for which there was less uncertainty, Steinman points out that some individuals in these groups chose the drugs that had no evidence of clinical benefit or a longer track record of safety.
"Simply adding warnings to patient educational materials is unlikely to meaningfully increase rational prescribing," he writes. "Nonetheless, giving patients warnings and instructions may be of substantial value if we also provide them the tools to help them successfully advocate for their own care." Steinman describes efforts to encourage patients to speak with their physicians about medication choices and to advocate for themselves. "Patient activation programs are a valuable tool to provide better care," he concludes. "We should take full advantage."
(Arch Intern Med. 2011;171[16]:1468-1469. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Dr. Steinman's work was supported by the National Institute on Aging and the American Federation for Aging Research. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact Steven Woloshin, M.D., M.S., call Deborah G. Kimbell at 603-650-6694 or e-mail deborah.kimbell@dartmouth.edu. To contact commentary author Michael A. Steinman, M.D., call Judi Cheary at 415-750-3350 or e-mail judi.cheary2@va.gov.
Journal
Archives of Internal Medicine